<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0106233759
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1994
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LOPID
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GEMFIBROZIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        49.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Pharma GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lopid contains the active substance gemfibrozil which belongs to a group of medicines commonly known as fibrates. These medicines are used to lower the level of fats (lipids) in the blood. For example the fats known as triglycerides.</p><p>&nbsp;</p><p>Lopid is used, alongside a low fat diet and other non-medical treatment such as exercise and weight loss, to lower levels of fat in the blood. Lopid can be used when other medicines (statins) are unsuitable, to reduce the occurrence of heart problems in men who are at high risk and who have increased &lsquo;bad cholesterol&rsquo;.</p><p>&nbsp;</p><p>Lopid may also be prescribed to people who cannot be prescribed other lipid-lowering medicines for lowering blood cholesterol levels.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lopid</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to gemfibrozil or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe kidney disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of gall stones, bile and gall bladder disease (biliary tract disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if in the past you have had photoallergy or a phototoxicity reaction (allergic reaction triggered by exposure to sunlight) during treatment with fibrates</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are currently taking a medicine called repaglinide (a drug used to reduce blood sugar levels in diabetes), simvastatin or rosuvastatin at 40 mg (cholesterol lowering medicines) or dasabuvir (a drug used to treat hepatitis C infection) or selexipag (a drug used to treat pulmonary arterial hypertension)</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or pharmacist before taking Lopid.</p><p>Tell your doctor if you have any of the following conditions to help decide if Lopid is suitable for you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high risk of muscle breakdown (rhabdomyolysis): risk factors include kidney impairment; under-active thyroid; over 70 years; excessive use of alcohol; previous history of muscular pain and weakness (muscular toxicity) with another fibrate or statin; a history of inherited muscular disorders; use of Lopid in combination with statins used to lower bad cholesterol and triglycerides, and increase good cholesterol such as rosuvastatin and simvastatin (for simvastatin and rosuvastatin 40 mg see &ldquo;Do not take Lopid&rdquo; and see &ldquo;Other medicines and Lopid&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mild or moderate kidney disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; under-active thyroid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes</p><p>&nbsp;</p><p><strong>Other medicines and Lopid</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-diabetic medication particularly rosiglitazone or repaglinide (used to help reduce blood sugar levels) (for repaglinide see &ldquo;Do not take Lopid&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dasabuvir, a drug used to treat hepatitis C infection (see &ldquo;Do not take Lopid&quot; above)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; selexipag, a treatment for pulmonary hypertension (see &ldquo;Do not take Lopid&quot; above)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; statins used to lower bad cholesterol and triglycerides, and increase good cholesterol such as atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin (for simvastatin and rosuvastatin at 40mg see &ldquo;Do not take Lopid&rdquo; and see &ldquo;Warnings and precautions&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dabrafenib, a treatment for melanoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loperamide, a treatment for diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; montelukast, a treatment for asthma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pioglitazone, a treatment used for diabetes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin, acenocoumarol, and phenprocoumon (anticoagulants used to thin blood)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; colestipol resin granules for the treatment of high levels of fat (cholesterol) in your blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bexarotene medication for the treatment of skin cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; colchicine for the treatment of gout</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paclitaxel, a treatment for cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enzalutamide, a treatment for prostate cancer</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><u>&nbsp;</u></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding </u></p><p>It is recommended that you do not take Lopid while you breast-feed.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>In rare cases Lopid may cause dizziness and affect your eyesight, if this happens, do not drive or operate machinery. You can drive or operate machinery as long as you feel well.</p><p>&nbsp;</p><p><strong>Dietary sodium</strong></p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet and therefore is essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Your blood lipid levels will be closely monitored and regularly assessed before and during your treatment with Lopid. If you are diabetic or have problems with your thyroid, your doctor will try to treat these conditions before you start treatment. Your doctor will also give you advice about eating the correct diet, exercising, giving up smoking, cutting down on alcohol and if necessary, losing weight.</p><p>&nbsp;</p><p>Lopid should be taken orally. It is recommended that the capsules or tablets be swallowed with a glass of water as the tablets taste unpleasant if you break them.</p><p>&nbsp;</p><p><strong>Lopid with food and drink</strong></p><p>&nbsp;</p><p>Lopid should be taken half an hour before meals.</p><p><strong>&nbsp;</strong></p><p><strong>Adults and elderly:</strong></p><p>&nbsp;</p><p>The usual starting dose is between 900 mg and 1200 mg daily. Your doctor will decide the best dose for you, follow the instructions given on the label.</p><p>&nbsp;</p><p>If you are advised to take a 1200 mg dose, you will need to take 600 mg half an hour before your breakfast and a second 600 mg half an hour before your evening meal.<br />&nbsp;</p><p>&nbsp;<strong>Adults with mild or moderate kidney disease:</strong></p><p>&nbsp;</p><p>Your doctor will assess your condition before and during your treatment with Lopid.</p><p>Lopid should not be used in patients with severe kidney disease.</p><p>&nbsp;</p><p><strong>Use in children </strong></p><p><strong>&nbsp;</strong></p><p>Lopid is not recommended for children.</p><p>&nbsp;</p><p><strong>If you take more Lopid than you should</strong></p><p>&nbsp;</p><p>If you accidentally take too much Lopid contact your doctor at once or go to the nearest hospital accident and emergency department. Always take the labelled medicine package with you, whether there is any Lopid left or not. Signs of overdose may be abdominal cramps, diarrhoea, joint and muscle pain, nausea and vomiting.</p><p>&nbsp;</p><p><strong>If you forget to take Lopid</strong></p><p>&nbsp;</p><p>If you forget to take a dose, do not worry. Simply miss that dose and take your next dose at the right time. <strong>Do not take a double dose to make up for a forgotten dose.</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking Lopid</strong></p><p>&nbsp;</p><p>Do not stop taking Lopid unless your doctor tells you to. <strong>It is recommended that you follow all the advice given while you are taking Lopid so as to gain the full benefit of the treatment</strong>.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong><strong> </strong></p><p><strong>&nbsp;</strong></p><p><strong>Although serious reactions can occur, you are advised to contact your doctor immediately if you get any of the following symptoms after taking Lopid:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction in which the face, tongue or throat may start to swell up, causing difficulty in breathing (angioedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; peeling and blistering of the skin, mouth, eyes and genitals</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash affecting your whole body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness or weakness accompanied by dark urine, fever, rapid heart rate (palpitations), nausea or vomiting</p><p><strong>&nbsp;</strong></p><p><strong>Other reported side effects include</strong>:</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p><strong>&nbsp;</strong></p><p>- indigestion</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects (may affect up to 1 in 10 people) </strong></p><p>&nbsp;</p><p>- sense of spinning or swaying (vertigo)</p><p>- eczema, rash (particularly an itchy or puffy rash)</p><p>- headache</p><p>- stomach pain</p><p>- diarrhoea</p><p>- feeling sick</p><p>- being sick</p><p>- constipation</p><p>- wind</p><p>- tiredness</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) </strong></p><p>&nbsp;</p><p>- irregular heartbeat</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people) </strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;- reduction or increase in white blood cells (leucopenia, eosinophilia), bone marrow disease (bone marrow failure)</p><p>- reduction of blood platelets (thrombocytopenia)</p><p>- inflammation of the nerves (peripheral neuropathy)</p><p>- unusual bruising or bleeding due to a reduction in blood platelets (thombocytopaenia)</p><p>- severe anaemia</p><p>- loss of feeling and a tingling sensation (paraesthesia)</p><p>- pancreatitis</p><p>- blurred vision</p><p>- jaundice (yellowing of the skin), disturbed liver function</p><p>- inflammation of the liver (hepatitis)</p><p>- gallstones (cholelithiasis), inflammation of the gall bladder (cholecystitis)</p><p>- appendicitis</p><p>- depression</p><p>- dizziness</p><p>- sleepiness</p><p>- painful joints and extremities</p><p>- inflammation of the skin or inflamed skin which flakes or falls off</p><p>- inflammation of the muscles (myositis)</p><p>- inflammation of the synovial membrane (synovitis)</p><p>- persistent lack of energy</p><p>- impotence</p><p>- decreased libido</p><p>- hair loss</p><p>- photosensitivity (a sensitivity to light that can cause skin discolouration or a rash)</p><p>- red, itchy raised areas of skin</p><p>- itching</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.<strong> </strong></p><p><strong>&nbsp;</strong></p><p>To reports any side effect(s):</p><p>&nbsp;</p><p><strong>Saudi Arabia: </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;Other GCC States:</strong></p><p><em>&nbsp;</em></p><p> Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton label and blister foil after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 25&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is gemfibrozil.</p><p>Each film-coated tablet contains 600 mg gemfibrozil</p><p>The other ingredients are pregelatinised starch, microcrystalline cellulose, colloidal silica (anhydrous), sodium starch glycollate, polysorbate 80 and magnesium stearate.</p><p>&nbsp;</p><p>The film coat for the tablets contains Methylhydroxypropylcellulose, titanium dioxide, Polyethylenesiloxane, polyethylene glycol and talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lopid 600 mg is a white oval film-coated tablet. It is packaged in PVC blister strips with an aluminium foil back in packs containing 30 tablets. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORISATION HOLDER</strong></p><p>&nbsp;</p><p>PFIZER PHARMA GmbH</p><p>Linkstr. 10</p><p>10785 Berlin, Germany</p><p>&nbsp;</p><p><strong>MANUFACUTRED BY</strong></p><p><strong>&nbsp;</strong></p><p>Pfizer Manufacturing Deutschland GmbH</p><p>Mooswaldallee 1</p><p>79090 Freiburg, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 July 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي لوبيد على المادة الفعالة جيمفيبروزيل التي تنتمي إلى مجموعة من الأدوية تُعرف باسم الفيبرات. تُستخدم هذه الأدوية لخفض مستوى الدهون (الشحوم) في الدم. على سبيل المثال الدهون المعروفة &nbsp;بالدهون الثلاثية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم لوبيد، إلى جانب اتباع نظام غذائي منخفض الدهون واستعمال علاجات أخرى غير طبية مثل ممارسة التمرينات الرياضية وفقدان الوزن، لخفض مستويات الدهون في الدم. يمكن استخدام لوبيد عندما تكون الأدوية الأخرى (الستاتينات) غير مناسبة، لخفض معدلات حدوث المشكلات القلبية لدى الرجال المعرضين للخطر بنسبة عالية والذين لديهم زيادة في مستويات &rsquo;الكوليسترول الضار&lsquo;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما يمكن أيضًا وصف لوبيد للأشخاص الذين لا يمكن أن يوصف لهم أي أدوية أخرى خافضة للدهون لخفض مستويات الكوليسترول في الدم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال لوبيد</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه جيمفيبروزيل أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم &quot;٦&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كبدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض حاد بالكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت في السابق من أمراض الحصوات الصفراوية والعصارة الصفراوية وأمراض المرارة (أمراض القنوات الصفراوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت في السابق بالأرجية ضوئية الإحداث أو رد فعل ضوئي سُمي (تفاعل حساسية يُستحَث بالتعرض لضوء الشمس) أثناء العلاج بالفيبرات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حاليًا دواءً يسمى ريباجلينيد (عقار يُستخدم لخفض مستويات السكر في الدم لمرضى السكري) أو سيمفاستاتين أو روسوفاستاتين بجرعة ٤۰ ملجم (دوائين خافضين للكوليسترول) أو داسابوفير (عقار يستخدم لعلاج عدوى التهاب الكبد الوبائي C) أو سيليكسيباج (عقار يُستخدم لعلاج ارتفاع ضغط الدم الشرياني الرئوي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال لوبيد</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول لوبيد.</p><p dir="RTL">أخبر طبيبك إذا كنت تعاني من الحالات المرضية التالية للمساعدة في تقرير إذا ما كان لوبيد مناسبًا لك:</p><p dir="RTL">خطورة متزايدة للتعرض لتحلل العضلات (انحلال الربيدات): تتضمن عوامل خطورة القصور الكلوي؛ خمول الغدة الدرقية؛ أن تكون أكبر من ٧۰ عامًا؛ الإفراط في استخدام الكحول؛ تاريخ سابق من الإصابة بألم وضعف العضلات (تسمم العضلات) عند استخدام أحد الفيبرات أو الستاتينات الأخرى؛ تاريخ من الإصابة بالاضطرابات العضلية الوراثية؛ استخدام لوبيد بالتزامن مع الستاتينات المستخدمة لخفض الكوليسترول الضار والدهون الثلاثية ولزيادة الكوليسترول الحميد مثل روسوفاستاتين وسيمفاستاتين (بالنسبة لسيمفاستاتين وروسوفاستاتين ٤۰ ملجم، انظر قسم &quot;موانع استعمال لوبيد&quot; وانظر قسم &quot;التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية&quot;)</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض كلوي طفيف أو متوسط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خمول الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة لمرض السكري وخاصةً روسيجليتازون أو ريباجلينيد (دواء يستخدم للمساعدة على خفض مستويات السكر في الدم) (بالنسبة لريباجلينيد انظر القسم &quot;لا تتناول لوبيد&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داسابوفير، عقار يستخدم لعلاج عدوى التهاب الكبد الوبائي C (انظر قسم &quot;لا تتناول لوبيد&quot; أعلاه)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيليكسيباج، علاج لارتفاع ضغط الدم الرئوي (انظر قسم &quot;موانع استعمال لوبيد&quot; أعلاه)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستاتينات المستخدمة لخفض الكوليسترول الضار والدهون الثلاثية ولزيادة الكوليسترول الحميد مثل أتورفاستاتين ولوفاستاتين وبرافاستاتين وروسوفاستاتين وسيمفاستاتين (بالنسبة لسيمفاستاتين وروسوفاستاتين بجرعة ٤۰ ملجم انظر قسم &quot;موانع استعمال لوبيد&quot; وانظر قسم &quot;الاحتياطات عند استعمال لوبيد&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دابرافينيب، علاج الأورام الميلانينية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوبيراميد، علاج للإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مونتيلوكاست، علاج للربو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيوجليتازون، علاج يُستخدم لمرض السكري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين، ، أسينوكومارول، و فينبروكومون (مضادات تجلط تستخدم لتخفيف كثافة الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حبيبات راتنج كوليستيبول المستخدمة لعلاج المستويات المرتفعة من الدهون (الكوليسترول) في الدم&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء بكساروتين المستخدم لعلاج سرطان الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولشيسين المستخدم لعلاج النقرس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باكليتاكسيل، علاج للسرطان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنزالوتاميد، وهو علاج لسرطان البروستاتا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملاً أو تخططين للحمل، فيجب سؤال طبيبك لطلب النصح قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية </u></p><p dir="RTL">يوصى بعدم تناولك لوبيد أثناء إرضاعك لطفلك رضاعة طبيعية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير لوبيد على القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب لوبيد في حالات نادرة الدوار وقد يؤثر على بصرك، إذا حدث ذلك، لا تقد السيارة أو تستخدم الآلات. يمكنك أن تقوم بالقيادة أو تشغيل الماكينات طالما أنك تشعر بأنك على ما يرام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات لوبيد</strong></p><p dir="RTL"><strong>الصوديوم الغذائي</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا المنتج الدوائي على أقل من ۱ مليمول من الصوديوم (۲۳ ملجم) في كل قرص ولذلك يُعد &quot;خاليًا من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستتم مراقبة مستويات الدهون في دمك عن كثب وسيتم تقييمها بصورة منتظمة قبل وأثناء علاجك بلوبيد. إذا كنت مصابًا بداء السكري أو تعاني من مشكلات في غدتك الدرقية، فسيحاول طبيبك أن يعالج هذه الحالات قبل أن تبدأ العلاج. كما سيعطيك طبيبك أيضًا نصائح حول تناول النظام الغذائي الصحيح وممارسة التمرينات الرياضية والإقلاع عن التدخين والإقلال من تناول الكحوليات وإذا اقتضت الحاجة، فقدان الوزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي تناول لوبيد عن طريق الفم. يوصى ببلع الكبسولات أو الأقراص مع كوب من الماء حيث أن طعم الأقراص يكون كريهًا إذا تم كسرها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول لوبيد مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي تناول لوبيد قبل الوجبات بنصف ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون والمسنون:&nbsp;&nbsp; </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تتراوح جرعة البدء المعتادة ما بين ۹۰۰ ملجم ۱۲۰۰ ملجم يوميًا. سيقرر طبيبك أفضل جرعة مناسبة لك، اتبع التوجيهات المكتوبة على البطاقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا وُصف لك تناول جرعة بمقدار ۱۲۰۰ ملجم، فستحتاج إلى تناول قرص ٦۰۰ ملجم قبل الإفطار بنصف ساعة وتناول قرص ٦۰۰ ملجم آخر قبل وجبتك المسائية بنصف ساعة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون الذين يعانون من مرض طفيف أو متوسط بالكلى:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بتقييم حالتك قبل وأثناء علاجك بلوبيد.&nbsp; ينبغي عدم استخدام لوبيد مع المرضى المصابين بمرض حاد بالكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام الدواء للأطفال </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يوصى باستخدام لوبيد لعلاج الأطفال</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من لوبيد</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا قمت بتناول جرعة زائدة من لوبيد عن طريق الخطأ، فاتصل بطبيبك فورًا أو اذهب إلى قسم الحوادث والطوارئ بأقرب مستشفى.&nbsp; احرص دومًا على إحضار عبوة الدواء المزودة بملصق بيانات الدواء معك، سواء كان بها أقراص لوبيد متبقية أو لا. قد تتمثل علامات الجرعة المفرطة في حدوث تقلصات بالبطن والإسهال وألم بالمفاصل والعضلات والغثيان والقيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نيسان تناول جرعة لوبيد</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت تناول إحدى الجرعات، فلا داعي للقلق. ببساطة، تجاوز تلك الجرعة وتناول جرعتك التالية في موعدها الصحيح. <strong>لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التوقف عن تناول لوبيد</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوقف عن تناول لوبيد إلا إذا طلب منك طبيبك ذلك. <strong>يوصى باتباع جميع النصائح المعطاة لك أثناء تناولك لوبيد وذلك للحصول على الاستفادة الكاملة من العلاج.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وإذا كانت لديك مزيد من الأسئلة بشأن استخدام هذا الدواء، فاطرحها على الطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>على الرغم من إمكانية حدوث تفاعلات خطيرة، إلا أننا ننصحك بالاتصال بطبيبك على الفور إذا ظهرت عليك أي من الأعراض التالية بعد تناول لوبيد:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة (قد تؤثر على فرد واحد بين كل </strong>۱۰۰۰<strong> </strong><strong>فرد) </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية قد يبدأ فيه الوجه أو اللسان أو الحلق بالتورم مما يسبب صعوبة التنفس (وذمة وعائية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقشر وتقرح الجلد والفم والعينين والأعضاء التناسلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يصيب جسمك بأكمله</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات أو الضعف مصحوبًا ببول داكن اللون أو الحمى أو تسارع معدل نبضات القلب (الخفقان) أو الغثيان أو القيء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تشمل الأعراض الجانبية الأخرى التي تم الإبلاغ عنها:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة جدًا (قد تؤثر على أكثر من فرد واحد بين كل </strong>۱۰<strong> </strong><strong>أفراد)</strong></p><p dir="RTL">- عسر الهضم</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الشائعة (قد تؤثر على فرد واحد بحد أقصى بين كل </strong>۱۰<strong> </strong><strong>أفراد) </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">- الشعور بالدوار أو التأرجح (الدوخة)</p><p dir="RTL">-الإكزيما، الطفح الجلدي (وخاصةً طفح جلدي مثير للحكة أو منتفخ)&nbsp;</p><p dir="RTL">- الصداع</p><p dir="RTL">- ألم في المعدة</p><p dir="RTL">- الإسهال</p><p dir="RTL">- الغثيان</p><p dir="RTL">- القئ</p><p dir="RTL">- الإمساك</p><p dir="RTL">- الغازات</p><p dir="RTL">- التعب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة (قد تؤثر على فرد واحد بحد أقصى بين كل </strong>۱۰۰<strong> </strong><strong>فرد) </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">- ضربات قلب غير منتظمة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تؤثر على فرد واحد بين كل </strong>۱۰۰۰<strong> </strong><strong>فرد)</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;- انخفاض أو زيادة تعداد خلايا الدم البيضاء (قلة الكريات البيض، كثرة اليوزينيات)، مرض نخاع العظام (فشل في نخاع العظام)</p><p dir="RTL">- انخفاض عدد الصفائح الدموية (قلة الصفيحات)</p><p dir="RTL">- التهاب الأعصاب (اعتلال الأعصاب الطرفية)</p><p dir="RTL">- &nbsp;تكدم أو نزيف غير طبيعي نتيجة انخفاض تعداد الصفائح الدموية (قلة الصفيحات)</p><p dir="RTL">- فقر الدم الحاد</p><p dir="RTL">- فقدان الإحساس والشعور بوخز (مذل)</p><p dir="RTL">- التهاب البنكرياس</p><p dir="RTL">- عدم وضوح الرؤية</p><p dir="RTL">- اليرقان (اصفرار الجلد)، اضطراب وظيفة الكبد</p><p dir="RTL">- التهاب الكبد (التهاب الكبد الوبائي)</p><p dir="RTL">- الحصوات الصفراوية (حصوات المرارة)، التهاب في المرارة<br />(الالتهاب المراري)</p><p dir="RTL">- التهاب الزائدة الدودية</p><p dir="RTL">- الاكتئاب</p><p dir="RTL">- الدوار</p><p dir="RTL">- النعاس</p><p dir="RTL">- ألم المفاصل والأطراف</p><p dir="RTL">- التهاب الجلد أو الجلد الملتهب الذي يتقشر أو يسقط</p><p dir="RTL">- التهاب العضلات (التهاب العضل)</p><p dir="RTL">- التهاب الغشاء الزليلي (التهاب الزليل)</p><p dir="RTL">- نقص الطاقة الدائم</p><p dir="RTL">- الضعف الجنسي</p><p dir="RTL">- انخفاض الرغبة الجنسية</p><p dir="RTL">- فقدان الشعر</p><p dir="RTL">- حساسية للضوء (حساسية تجاه الضوء يمكن أن تسبب تغير لون الجلد أو طفحًا جلديًا)</p><p dir="RTL">- مناطق من الجلد تكون حمراء بارزة ومثيرة للحكة</p><p dir="RTL">- الحكة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ظهرت عليك أي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يشتمل هذا على أي أعراض جانبية محتملة وغير مدرجة في هذه النشرة. بإبلاغك عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحت أي من الأعراض الجانبية خطيرة، أو إذا لاحظت أي أعراض جانبية غير مدرجة في هذه النشرة، يُرجى إخبار طبيبك أو مقدم الرعاية الصحية الخاص بك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن الأعراض الجانبية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرقم المجاني: ۱٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دول الخليج الأخرى:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المكتوب على ملصق الكرتونة أو غلاف شريط الدواء بعد انتهاء تاريخ الصلاحية &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن عند درجة حرارة لا تزيد عن ۲٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم التخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. تساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ملجم المادة الفعالة هي جيمفيبروزيل.</p><p dir="RTL">يحتوي كل قرص مغلف بطبقة رقيقة على ٦۰۰ ملجم من جيمفيبروزيل.</p><p dir="RTL">المكونات الأخرى هي نشا مسبق التجلتن وسليولوز بلوري مكروي وسيليكا غروية (لامائية) وجليكولات نشا الصوديوم وبوليسوربات ۸۰ وستيارات المغنيسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي الغلاف الرقيق للأقراص على ميثيل هيدروكسي بروبيل سيليلوز وثنائي أكسيد التيتانيوم&nbsp; وسيلوكسان بولي إيثيلين وجليكول البولي إيثيلين والتلك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص لوبيد ٦۰۰ ملجم هي أقراص بيضاء بيضاوية الشكل مغلفة بطبقة رقيقة. وهي معبأة في شرائط فقاعية مصنوعة من كلوريد البولي فينيل تغطيها رقاقة من الألومنيوم في عبوات تحتوي على ۳۰ قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">Pfizer Pharma GmbH</p><p dir="RTL">&nbsp;10 Linkstr</p><p dir="RTL">10785 Berlin, Germany</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة</strong></p><p dir="RTL">Pfizer Manufacturing Deutschland GmbH</p><p dir="RTL">Mooswaldallee 1</p><p dir="RTL">79090 Freiburg, Germany، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو/تموز ۲۰۲۰
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lopid 600 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 600 mg of gemfibrozil.
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet

Description

Lopid 600 mg: white, biconvex, oval, film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lopid is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following:</p><p>- Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.</p><p>- Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.</p><p>- Primary hypercholesterolaemia when a statin is contraindicated or not tolerated.</p><p>&nbsp;</p><p><u>Primary prevention</u></p><p>Reduction of cardiovascular morbidity in males with increased non-HDL cholesterol and at high risk for a first cardiovascular event when a statin is contraindicated or not tolerated (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prior to initiating gemfibrozil, other medical problems such as hypothyroidism and diabetes mellitus must be controlled as best as possible and patients should be placed on a standard lipid-lowering diet, which should be continued during treatment. Lopid should be taken orally.</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p><u>Adult</u></p><p>The dose range is 900 mg to 1200 mg daily.</p><p>The only dose with documented effect on morbidity is 1200 mg daily.</p><p>&nbsp;</p><p>See Method of administration.</p><p>&nbsp;</p><p><u>Elderly (over 65 years old)</u></p><p>As for adults</p><p>&nbsp;</p><p><u>Children and adolescent<strong><em>s</em></strong></u></p><p>Gemfibrozil therapy has not been investigated in children. Due to the lack of data the use of Lopid in children is not recommended.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>In patients with mild to moderate renal impairment (Glomerular filtration rate 50 - 80 and 30 &lt; 50 ml/min/1.73 m<sup>2</sup>, respectively), Lopid should not be used in patients with severely impaired renal function (see section 4.3).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Gemfibrozil is contraindicated in hepatic impairment (see section 4.3).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>The 1200 mg dose is taken as 600 mg twice daily, half an hour before breakfast and half an hour before the evening meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Hepatic impairment
•	Severe renal impairment
•	History of/or pre-existing gall bladder or biliary tract disease, including gallstones
•	Concomitant use of repaglinide, dasabuvir, selexipag (see section 4.5), simvastatin, or rosuvastatin at 40 mg (see sections 4.4 and 4.5)
•	Patients with previous history of photoallergy or phototoxic reaction during treatment with fibrates

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Muscle disorders (myopathy/rhabdomyolysis)</u></p><p>There have been reports of myositis, myopathy and markedly elevated creatine</p><p>phosphokinase associated with gemfibrozil. Rhabdomyolysis has also been reported rarely.</p><p>&nbsp;</p><p>Muscle damage must be considered in any patient presenting with diffuse myalgia, muscle tenderness and/or marked increase in muscle CPK levels (&gt;5x ULN); under these conditions treatment must be discontinued.</p><p>&nbsp;</p><p><u>Concomitant HMG CoA reductase inhibitors</u></p><p>The concomitant administration of gemfibrozil with simvastatin, as well as with rosuvastatin at 40 mg is contraindicated. Concomitant therapy of gemfibrozil with lower doses of rosuvastatin should be used only when the benefit outweighs the risks. There have been reports of severe myositis with markedly elevated creatine kinase and myoglobinuria (rhabdomyolysis) when gemfibrozil and HMG CoA reductase inhibitors were used concomitantly (see sections 4.3 and 4.5). Pharmacokinetic interactions may also be present (see also section 4.5) and dosage adjustments may be necessary.</p><p>&nbsp;</p><p>The benefit of further alterations in lipid levels by the combined use of gemfibrozil and HMG-CoA reductase inhibitors should be carefully weighed against the potential risks of such combinations and clinical monitoring is recommended.</p><p>&nbsp;</p><p>A creatine phosphokinase (CPK) level should be measured before starting such a combination in patients with pre-disposing factors for rhabdomyolysis as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypothyroidism</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alcohol abuse</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; age &gt; 70 years</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; personal or family history of hereditary muscular disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; previous history of muscular toxicity with another fibrate or HMG-CoA reductase inhibitor</p><p>&nbsp;</p><p>In most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with HMG-CoA reductase inhibitors and gemfibrozil does not outweigh the risks of severe myopathy, rhabdomyolysis and acute renal failure.</p><p><u>&nbsp;</u></p><p><u>Use in patients with gallstone formation</u></p><p>Gemfibrozil may increase cholesterol excretion into the bile raising the potential for gallstone formation. Cases of cholelithiasis have been reported with gemfibrozil therapy. If cholelithiasis is suspected, gallbladder studies are indicated. Gemfibrozil therapy should be discontinued if gallstones are found.</p><p><u>&nbsp;</u></p><p><u>Monitoring serum lipids</u></p><p>Periodic determinations of serum lipids are necessary during treatment with gemfibrozil. Sometimes a paradoxical increase of (total and LDL) cholesterol can occur in patients with hypertriglyceridaemia. If the response is insufficient after 3 months of therapy at recommended doses treatment should be discontinued and alternative treatment methods considered.</p><p>&nbsp;</p><p><u>Monitoring liver function</u></p><p>Elevated levels of ALAT, ASAT, alkaline phosphatase, LDH, CK and bilirubin have been reported. These are usually reversible when gemfibrozil is discontinued. Therefore liver function tests should be performed periodically. Gemfibrozil therapy should be terminated if abnormalities persist.</p><p>&nbsp;</p><p><u>Monitoring blood counts</u></p><p>Periodic blood count determinations are recommended during the first 12 months of gemfibrozil administration. Anaemia, leucopenia, thrombocytopenia, eosinophilia and bone marrow hypoplasia have been reported rarely (see section 4.8).</p><p><u>&nbsp;</u></p><p><u>Interactions with other medicinal products (see also sections 4.3 and 4.5) </u></p><p><em>Concomitant use with CYP2C8, CYP2C9, CYP2C19, CYP1A2, UGTA1, UGTA3 and OATP1B1 substrates</em></p><p>The interaction profile of gemfibrozil is complex resulting in increased exposure of many medicinal products if administered concomitantly with gemfibrozil.</p><p>&nbsp;</p><p>Gemfibrozil potently inhibits CYP2C8, CYP2C9, CYP2C19, CYP1A2, and UDP glucuronyltransferase (UGTA1 and UGTA3) enzymes and also inhibits organic anion-transporting polypeptide 1B1 (OATP1B1) (see section 4.5). In addition, gemfibrozil is metabolised to gemfibrozil 1-O-&beta;-glucuronide which also inhibits CYP2C8 and OATP1B1.</p><p>&nbsp;</p><p><em>Concomitant use with hypoglycaemic agents</em></p><p>There have been reports of hypoglycaemic reactions after concomitant use with gemfibrozil and hypoglycaemic agents (oral agents and insulin). Monitoring of glucose levels is recommended.</p><p>&nbsp;</p><p><em>Concomitant anticoagulants</em></p><p>Gemfibrozil may potentiate the effects of coumarin type vitamin K antagonist anticoagulants such as warfarin, acenocoumarol, or phenprocoumon. The concomitant administration of gemfibrozil with these anticoagulants necessitates careful monitoring of prothrombin time (INR - International Normalised Ratio). Caution should be exercised when such a coumarin type vitamin K antagonist anticoagulant is given concomitantly with gemfibrozil. The dosage of the anticoagulant may need to be reduced to maintain desired prothrombin time levels (see section 4.5).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Dietary sodium</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23 mg) per tablet. Patients on low sodium diets should be informed that this medicinal product is essentially &lsquo;sodium‑free&rsquo;.</p><p><strong><u>&nbsp;</u></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The interaction profile of gemfibrozil is complex. In vivo studies indicate that gemfibrozil and its metabolite gemfibrozil 1-O-&beta;-glucuronide are potent inhibitors of CYP2C8 (an enzyme important for the metabolism of e.g. dabrafenib, enzalutamide, loperamide, montelukast, repaglinide, rosiglitazone, pioglitazone, dasabuvir, selexipag and paclitaxel). Co-administration of gemfibrozil with repaglinide,&nbsp; dasabuvir or selexipag is contraindicated (see section 4.3). In addition, dosing reduction of drugs that are mainly metabolised by CYP2C8 enzyme may be required when gemfibrozil is used concomitantly. In vitro studies have shown that gemfibrozil is a strong inhibitor of CYP2C9 (an enzyme involved in the metabolism of e.g. warfarin and glimepiride), but also of CYP 2C19, CYP1A2, OATP1B1 and UGTA1 and UGTA3 (see section 4.4). Gemfibrozil 1‑O-&beta;-glucuronide also inhibits OATP1B1.</p><p>&nbsp;</p><p><u>Repaglinide</u></p><p>In healthy volunteers, co-administration with gemfibrozil increased the AUC and C<sub>max</sub> of repaglinide by 8.1-fold and 2.4-fold, respectively. In the same study, co‑administration with gemfibrozil and itraconazole increased the AUC and C<sub>max</sub> of repaglinide by 19.4-fold and 2.8-fold, respectively. In addition, co‑administration with gemfibrozil or with gemfibrozil and itraconazole prolonged its hypoglycaemic effects. Therefore, co‑administration of gemfibrozil and repaglinide increases the risk for severe hypoglycaemia and is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><u>Dasabuvir</u></p><p>Co‑administration of gemfibrozil with dasabuvir increased dasabuvir AUC and C<sub>max</sub> (ratios: 11.3 and 2.01, respectively) due to CYP2C8 inhibition. Increased dasabuvir exposure may increase the risk of QT prolongation, therefore, co‑administration of gemfibrozil with dasabuvir is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><u>Selexipag</u></p><p>Co-administration of gemfibrozil with selexipag,<em> </em>a substrate for CYP2C8, doubled exposure (AUC) to selexipag and increased exposure (AUC) to the active metabolite, ACT-333679, by approximately 11- fold. Concomitant administration of gemfibrozil with selexipag is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><u>Enzalutamide</u></p><p>In healthy volunteers given a single 160 mg dose of enzalutamide after gemfibrozil 600 mg twice daily, the AUC of enzalutamide plus active metabolite (N-desmethyl enzalutamide) was increased by 2.2-fold and corresponding C<sub>max</sub> was decreased by 16%. Increased enzalutamide exposure may increase the risk of seizures. Concomitant treatment of gemfibrozil and enzalutamide should be avoided; if co-administration is considered necessary, the dose of enzalutamide should be reduced (see section 4.4).</p><p>&nbsp;</p><p><u>Rosiglitazone</u></p><p>The combination of gemfibrozil with rosiglitazone should be approached with caution. Co-administration with rosiglitazone has resulted in 2.3-fold increase in rosiglitazone systemic exposure, probably by inhibition of the CYP2C8 isozyme (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>HMG CoA reductase inhibitors</u></p><p>The concomitant administration of gemfibrozil with simvastatin, as well as with rosuvastatin at 40 mg is contraindicated (see sections 4.3 and 4.4). The combined use of gemfibrozil and a statin should generally be avoided (see section 4.4). The use of fibrates alone is occasionally associated with myopathy. An increased risk of muscle related adverse events, including rhabdomyolysis, has been reported when fibrates are co-administered with statins.</p><p><s>&nbsp;</s></p><p>Gemfibrozil has also been reported to influence the pharmacokinetics of simvastatin, lovastatin, pravastatin, rosuvastatin and atorvastatin. Gemfibrozil caused an almost 3-fold increased in AUC of simvastatin acid possibly due to inhibition of glucoronidation via UGTA1 and UGTA3, and a 3-fold increase in pravastatin AUC which may be due to interference with transport proteins. One study indicated that the co-administration of a single rosuvastatin dose of 80 mg to healthy volunteers on gemfibrozil (600mg twice daily) resulted in a 2.2-fold increase in mean C<sub>max</sub> and a 1.9-fold increase in mean AUC of rosuvastatin. The co-administration of a single lovastatin dose of 40 mg with gemfibrozil (600 mg twice daily for 3 days) in healthy volunteers resulted in a 2.8-fold increase of the mean AUC and C<sub>max </sub>of lovastatin acid. The co-administration of a single atorvastatin dose of 40 mg with gemfibrozil (600 mg twice daily for 7 days) in healthy volunteers resulted in a 1.35-fold increase in mean AUC and no increase in mean C<sub>max </sub>of atorvastatin.</p><p>&nbsp;</p><p><u>Anticoagulants</u></p><p>Gemfibrozil may potentiate the effects of coumarin type vitamin K antagonist anticoagulants such as warfarin, acenocoumarol, or phenprocoumon. The concomitant administration of gemfibrozil with these anticoagulants necessitates careful monitoring of prothrombin time (INR) (see section 4.4).</p><p>&nbsp;</p><p><u>Bexarotene</u></p><p>Concomitant administration of gemfibrozil with bexarotene is not recommended. A population analysis of plasma bexarotene concentrations in patients with cutaneous T-cell lymphoma (CTCL) indicated that concomitant administration of gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene.</p><p>&nbsp;</p><p><u>Bile acid &ndash; binding resins</u></p><p>Reduced bioavailability of gemfibrozil may result when given simultaneously with resin-granule drugs such as colestipol. Administration of the products two hours or more apart is recommended.</p><p>&nbsp;</p><p><u>Colchicine</u></p><p>Risk of myopathy and rhabdomyolysis may be increased with concomitant administration of colchicine and gemfibrozil. This risk may be increased in the elderly and in patients with hepatic or renal dysfunction. Clinical and biological monitoring are recommended, especially at the start of combined treatment.</p><p>&nbsp;</p><p>Gemfibrozil is highly bound to plasma proteins and there is potential for displacement interactions with other drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data on use of Lopid in pregnant women. Animal studies are insufficiently clear to allow conclusions to be drawn on pregnancy and foetal development (see section 5.3). The potential risk for humans is unknown. Lopid should not be used during pregnancy unless it is clearly necessary.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There are no data on excretion of gemfibrozil in milk. Lopid should not be used when breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Reversible decreases in male fertility have been observed in reproductive toxicity studies in rats (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. In isolated cases dizziness and visual disturbances can occur which may negatively influence driving.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Most commonly reported adverse reactions are of gastrointestinal character and are seen in approximately 7% of the patients. These adverse reactions do not usually lead to discontinuation of the treatment.</p><p><s>&nbsp;</s></p><p>Adverse reactions are ranked according to frequency using the following convention: Very common (<u>&gt;</u>1/10), Common (<u>&gt;</u>1/100 to &lt;1/10), Uncommon (<u>&gt;</u>1/1,000 to &lt;1/100), Rare (<u>&gt;</u>1/10,000 to &lt;1/1,000), Very rare (&lt;1/10,000), including isolated reports:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable effect</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bone marrow failure, severe anaemia, thrombocytopenia, leukopenia, eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Depression, decreased libido</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vertigo, headache</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Neuropathy peripheral, paraesthesia, dizziness, somnolence</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vision blurred</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Atrial fibrillation</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Laryngeal oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea, vomiting, nausea, abdominal pain constipation, flatulence</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pancreatitis, appendicitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Jaundice cholestatic, hepatitis, cholelithiasis, cholecystitis, hepatic function abnormal</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Eczema, rash</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema, dermatitis exfoliative, urticaria, dermatitis, alopecia, photosensitivity reaction, pruritus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rhabdomyolysis, myopathy, myositis, muscular weakness, synovitis, myalgia, arthralgia, pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorder</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Haemoglobin decreased, haematocrit decreased, white blood cell count decreased, blood creatine phosphokinase increased</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local country requirements</u>.</p><p><strong>&nbsp;</strong></p><p>To reports any side effect(s):</p><p>&nbsp;</p><p><strong>Saudi Arabia: </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><ul><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;Other GCC States:</strong></p><p><em>&nbsp;</em></p><p> Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose has been reported. Symptoms reported with overdosage were abdominal cramps, abnormal LFT&rsquo;s, diarrhea, increased CPK, joint and muscle pain, nausea and vomiting. The patients fully recovered. Symptomatic supportive measures should be taken if overdose occurs.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Serum-lipid lowering agent</p><p>Chemical subgroup: Fibrates</p><p>ATC code: C10A B04</p><p>&nbsp;</p><p>Gemfibrozil is a non-halogenated phenoxypentanoic acid. Gemfibrozil is a lipid regulating agent which regulates lipid fractions.</p><p>&nbsp;</p><p>Gemfibrozil&#39;s mechanism of action has not been definitively established. In man, gemfibrozil stimulates the peripheral lipolysis of triglyceride rich lipoproteins such as VLDL and cholymicrons (by stimulation of LPL). Gemfibrozil also inhibits synthesis of VLDL in the liver. Gemfibrozil increases the HDL<sub>2</sub> and HDL<sub>3</sub> subfractions as well as apolipoprotein A-I and A-II.</p><p><strong><em>&nbsp;</em></strong></p><p>Animal studies suggest that the turnover and removal of cholesterol from the liver is increased by gemfibrozil.</p><p>&nbsp;</p><p>There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all-cause mortality in the primary or secondary prevention of cardiovascular disease.</p><p>&nbsp;</p><p>In the Helsinki Heart Study, which was a large placebo-controlled study with 4081 male subjects, 40 to 55 years of age, with primary dyslipidaemia (predominantly raised non-HDL cholesterol +/- hypertriglyceridaemia), but no previous history of coronary heart disease, gemfibrozil 600 mg twice daily, produced a significant reduction in total plasma triglycerides, total and low density lipoprotein cholesterol and a significant increase in high density lipoprotein cholesterol. The cumulative rate of cardiac end-points (cardiac death and non-fatal myocardial infarction) during a 5 year follow-up was 27.3/1,000 in the gemfibrozil group (56 subjects) and 41.4/1000 in the placebo group (84 subjects) showing a relative risk reduction of 34.0% (95% confidence interval 8.2 to 52.6, p&lt;0.02) and an absolute risk reduction of 1.4% in the gemfibrozil group compared to placebo. There was a 37% reduction in non-fatal myocardial infarction and a 26% reduction in cardiac deaths. The number of deaths from all causes was, however, not different (44 in the gemfibrozil group and 43 in the placebo group). Diabetes patients and patients with severe lipid fraction deviations showed a 68% and 71% reduction of CHD endpoints, respectively.</p><p>&nbsp;</p><p>The VA-HIT study was a double-blind study comparing gemfibrozil (1200 mg per day) with placebo in 2531 men with a history of coronary heart disease, HDL-C levels of &lt; 40 mg/dL (1.0 mmol/L), and normal LDL C levels. After one year, the mean HDL-C level was 6% higher and the mean triglyceride level was 31% lower in the gemfibrozil group than in the placebo group. The primary event of non-fatal myocardial infarction or cardiac death occurred in 17.3% of gemfibrozil-treated and 21.7% of placebo-treated patients (reduction in relative risk 22%; 95% CI, 7 to 35 %; P=0.006). Among secondary outcomes, patients treated with gemfibrozil experienced relative risk reductions of 25% (95% CI&ndash;6-47%, p=0.10) for stroke, 24% (95% CI 11-36%, p&lt; 0.001) for the combined outcome of death from CHD, non-fatal myocardial infarction, or confirmed stroke, 59% (95% CI 33-75%, p&lt;0.001) for transient ischaemic attack, and 65% (95% CI 37-80%, p&lt; 0.001) for carotid endarterectomy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Gemfibrozil is well absorbed from the gastro-intestinal tract after oral administration with a bioavailability close to 100%. As the presence of food alters the bioavailability slightly gemfibrozil should be taken 30 minutes before a meal. Peak plasma levels occur in one to two hours. After administration of 600 mg twice daily a C<sub>max</sub> in the range 15 to 25 mg/L is obtained.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Volume of distribution at steady state is 9-13 L. The plasma protein binding of gemfibrozil and its main metabolite are at least 97%.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Biotransformation</u></p><p>Gemfibrozil undergoes oxidation of a ring methyl group to form successively a hydroxymethyl and a carboxyl metabolite (the main metabolite). This metabolite has a low activity compared to the mother compound gemfibrozil and an elimination half-life of approximately 20 hours. Glucuronidation to gemfibrozil 1-O-&beta;-glucuronide is another important elimination pathway for gemfibrozil in man.</p><p>&nbsp;</p><p>The enzymes involved in the metabolism of gemfibrozil are not known. The interaction profile of gemfibrozil and its metabolites is complex (see sections 4.3, 4.4 and 4.5). In vitro and in vivo studies have shown that gemfibrozil inhibits CYP2C8, CYP2C9, CYP2C19, CYP1A2, UGTA1, UGTA3 and OATP1B1. Gemfibrozil 1-O-&beta;-glucuronide also inhibits CYP2C8 and OATP1B1.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>Gemfibrozil is eliminated mainly by metabolism. Approximately 70% of the administered human dose is excreted in the urine, mainly as conjugates of gemfibrozil and its metabolites. Less than 6% of the dose is excreted unchanged in the urine. Six percent of the dose is found in faeces. The total clearance of gemfibrozil is in the range 100 to 160 ml/min, and the elimination half-life is in the range 1.3 to 1.5 hours. The pharmacokinetics is linear within the therapeutic dose range.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Special patient groups</u></p><p>No pharmacokinetic studies have been performed in patients with impaired hepatic function.</p><p>There are limited data on patients with mild, moderate and non-dialysed severe renal impairment. The limited data support the use of up to 1200 mg a day in patients with mild to moderate renal failure not receiving another lipid lowering drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a 2-year study of gemfibrozil, subcapsular bilateral cataracts occurred in 10%, and unilateral in 6.3%, of male rats treated at 10 times the human dose.</p><p>&nbsp;</p><p>In a mouse carcinogenicity study at dosages corresponding to 0.1 and 0.7 times the clinical exposure (based on AUC), there were no significant differences from controls in the incidence of tumours. In a rat carcinogenicity study at dosages corresponding to 0.2 and 1.3 times the clinical exposure (based on AUC), the incidence of benign liver nodules and liver carcinomas was significantly increased in high dose males, and the incidence of liver carcinomas increased also in the low dose males, but this increase was not statistically significant.</p><p>&nbsp;</p><p>Liver tumours induced by gemfibrozil and other fibrates in small rodents are generally considered to be related to the extensive proliferation of peroxisomes in these species and, consequently, of minor clinical relevance.</p><p>&nbsp;</p><p>In the male rat, gemfibrozil also induced benign Leydig cell tumours. The clinical relevance of this finding is minimal.</p><p>&nbsp;</p><p>In reproductive toxicity studies, administration of gemfibrozil at approximately 2 times the human dose (based on body surface area) to male rats for 10 weeks resulted in decreased fertility. Fertility was restored after a drug-free period of 8 weeks. Gemfibrozil was not teratogenic in either rats or rabbits. Administration of 1 and 3 times the human dose (based on body surface area) of gemfibrozil to female rabbits during organogenesis caused a dose-related decrease in litter size. Administration of 0.6 and 2 times the human dose (based on body surface area) of gemfibrozil to female rats from gestation Day 15 through weaning caused dose-related decreases in birth weight and suppression of pup growth during lactation. Maternal toxicity was observed in both species and the clinical relevance of decreases in rabbit litter size and rat pup weight is uncertain.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Core tablet:</strong></p><p>Microcrystalline cellulose</p><p>Pregelatinised starch</p><p>Colloidal silica (anhydrous)</p><p>Polysorbate 80</p><p>Sodium starch glycollate</p><p>Magnesium stearate</p><p>&nbsp;</p><p><strong>Tablet coating:</strong></p><p>Methylhydroxypropylcellulose</p><p>Titanium dioxide</p><p>Talc</p><p>Polydimethyl siloxane</p><p>Polyethylene glycol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Lopid after the expiry date which is stated on the carton / Blister after EXP:. The expiry date refers to the last day of that month.

36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.</p><p><strong>&nbsp;</strong></p><p>Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/Aluminium blisters with&nbsp; 30 tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORIZATION HOLDER

PFIZER PHARMA GmbH
Linkstr. 10
10785 Berlin
Germany
 

MANUFACUTRED BY

Pfizer Manufacturing Deutschland GmbH
Mooswaldallee 1
79090 Freiburg, Germany


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2021  
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>